Clay Siegall
Chief Executive Officer bij IMMUNOME, INC.
Vermogen: 8 M $ op 29-02-2024
Profiel
Clay B. Siegall, oprichter van Seagen Inc., is voorzitter, president & chief executive officer bij dit bedrijf. Dr. Siegall zit ook in de raad van bestuur van 5 andere bedrijven. In het verleden bekleedde hij de functie van Principal Scientist bij het Bristol-Myers Squibb Pharmaceutical Research Institute. Hij behaalde een bachelordiploma aan de Universiteit van Maryland en een doctoraat aan de George Washington Universiteit.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
IMMUNOME, INC.
0.57% | 02-10-2023 | 319 636 ( 0.57% ) | 8 M $ | 29-02-2024 |
-.--% | 13-12-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Clay Siegall
Bedrijven | Functie | Begin |
---|---|---|
IMMUNOME, INC. | Chief Executive Officer | 02-10-2023 |
SHATTUCK LABS, INC. | Director/Board Member | 01-03-2024 |
Washington Roundtable
Washington Roundtable Miscellaneous Commercial ServicesCommercial Services Washington Roundtable works to affect positive change on public policy issues that are most important to supporting state economic vitality and fostering opportunity. Its work includes sharing news and analysing policy developments. The company was founded in 1983 and is headquartered in Seattle, WA. | Director/Board Member | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Chairman | 13-12-2023 |
The Pacific Northwest Research Institute, Inc.
The Pacific Northwest Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services The Pacific Northwest Research Institute, Inc. is a non-profit organization, which engages in the biomedical research. The interests of the Institute’s investigators range from genetic and genomic studies on the cellular and metabolic processes that lead to cancer and neurological defects to foundational and clinical studies on pancreatic function and diabetes. The company was founded by William Hutchinson in 1956 and is headquartered in Seattle, WA. | Director/Board Member | - |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | 14-12-2012 |
Washington Biotechnology & Biomedical Association | Director/Board Member | - |
Eerdere bekende functies van Clay Siegall
Bedrijven | Functie | Einde |
---|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Chief Executive Officer | 01-10-2023 |
NURIX THERAPEUTICS, INC. | Director/Board Member | 15-05-2022 |
░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Opleiding van Clay Siegall
George Washington University | Doctorate Degree |
University of Maryland | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
IMMUNOME, INC. | Health Technology |
ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
NURIX THERAPEUTICS, INC. | Health Technology |
SHATTUCK LABS, INC. | Health Technology |
Bedrijven in privébezit | 11 |
---|---|
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Washington Roundtable
Washington Roundtable Miscellaneous Commercial ServicesCommercial Services Washington Roundtable works to affect positive change on public policy issues that are most important to supporting state economic vitality and fostering opportunity. Its work includes sharing news and analysing policy developments. The company was founded in 1983 and is headquartered in Seattle, WA. | Commercial Services |
Washington Biotechnology & Biomedical Association | |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
The Pacific Northwest Research Institute, Inc.
The Pacific Northwest Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services The Pacific Northwest Research Institute, Inc. is a non-profit organization, which engages in the biomedical research. The interests of the Institute’s investigators range from genetic and genomic studies on the cellular and metabolic processes that lead to cancer and neurological defects to foundational and clinical studies on pancreatic function and diabetes. The company was founded by William Hutchinson in 1956 and is headquartered in Seattle, WA. | Commercial Services |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Commercial Services |